Hutchison China Meditech Limited Notice of Results (9140D)

TIDMHCM

RNS Number : 9140D

Hutchison China Meditech Limited

25 February 2020

Chi-Med to announce 2019 Final Results on Tuesday, March 3, 2020 - adjustment to announcement and presentation logistics due to travel restrictions

London: Tuesday, February 25, 2020: Further to its announcement dated January 31, 2020, Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) announced that its final results for the year ended December 31, 2019 will be released on Tuesday, March 3, 2020. The time has been revised to 12:00 noon Greenwich Mean Time (GMT) / 7:00 am Eastern Standard Time (EST) / 8:00 pm Hong Kong Time (HKT).

Due to travel restrictions resulting from the novel coronavirus outbreak, Chi-Med management will not be travelling to London for a live presentation for analysts and investors. Analysts and investors are instead invited to join a conference call and audio webcast presentation with Q&A, conducted by Chi-Med management in Hong Kong and China.

The conference call and audio webcast will take place at 1:00 pm GMT / 8:00 am EST / 9:00 pm HKT on Tuesday, March 3, 2020 and will be webcast live via the company website at www.chi-med.com/investors/event-information/. The presentation will be available for downloading before the conference call begins. Details of the conference call dial-in will be provided in the financial results announcement and on the company website. A replay will also be available on the website shortly after the event.

About Chi-Med

Chi-Med (AIM/Nasdaq: HCM) is an innovative biopharmaceutical company which researches, develops, manufactures and markets pharmaceutical products. Its Innovation Platform, Hutchison MediPharma, has about 500 scientists and staff focusing on discovering, developing and commercializing targeted therapeutics and immunotherapies for the treatment of cancer and autoimmune diseases. It has a portfolio of eight cancer drug candidates currently in clinical studies around the world. Chi-Med's Commercial Platform manufactures, markets, and distributes prescription drugs and consumer health products, covering an extensive network of hospitals across China.

Chi-Med is headquartered in Hong Kong and is dual-listed on the AIM market of the London Stock Exchange and the Nasdaq Global Select Market. For more information, please visit: www.chi-med.com.

CONTACTS

 
Investor Enquiries 
  Mark Lee, Senior Vice President                             +852 2121 8200 
  Annie Cheng, Vice President                                 +1 (973) 567 3786 
  David Dible, Citigate Dewe Rogerson                         +44 7967 566 919 (Mobile) 
                                                               david.dible@citigatedewerogerson.com 
  Xuan Yang, Solebury Trout                                   +1 (415) 971 9412 (Mobile) 
                                                               xyang@troutgroup.com 
 
Media Enquiries 
  UK & Europe - Anthony Carlisle, Citigate Dewe Rogerson      +44 7973 611 888 (Mobile) 
                                                               anthony.carlisle@cdrconsultancy.co.uk 
  Americas - Brad Miles, Solebury Trout                       +1 (917) 570 7340 (Mobile) 
                                                               bmiles@troutgroup.com 
  Hong Kong & Asia ex-China     - Joseph Chi Lo, Brunswick    +852 9850 5033 (Mobile) 
                                                               jlo@brunswickgroup.com 
                                - Zhou Yi, Brunswick          +852 97 83 6894 (Mobile) 
                                                               y zhou@brunswickgroup.com 
  Mainland China - Sam Shen, Edelman                          +86 136 7179 1029 (Mobile) 
                                                               sam.shen@edelman.com 
 
Nominated Advisor 
  Atholl Tweedie, Panmure Gordon (UK) Limited                 +44 (20) 7886 2500

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

NORGZGZZMDNGGZM

(END) Dow Jones Newswires

February 25, 2020 02:00 ET (07:00 GMT)

Hutchison China Meditech (LSE:0J7G)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024